Ifosfamide in combined hormonochemotherapy on prostate cancer
Fujita, K.; Matsushima, H.; Nakano, M.; Kaneko, T.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 21(2): 227-230
1994
ISSN/ISBN: 0385-0684 PMID: 8311493 Document Number: 426802
In 1987, we altered the protocol of hormonochemotherapy on prostate cancer from the combination of oral UFT (futraful with uracil) and cyclophosphamide to oral UFT and intravenous ifosfamide, 3 g once a week for 3 weeks. Sixty-three patients with poorly differentiated and/or advanced prostate cancer were treated with the protocol. Although this study had no control group and the result was preliminary, prognosis of 21 patients without bone metastasis were satisfactory and none died. The 3-year survival rate of 28 patients with bone metastases less than 5 foci (EOD) was 81.3%, and that of 14 patients with multiple bone metastases was 48.8% (p < 0.001). This subclassification is useful to analyze and determine the prognosis.